Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)
Classic Kaposi Sarcoma
DRUG: Nivolumab|DRUG: Ipilimumab
ORR, overall response rate (ORR), 6-months
PFS rate, 6-months PFS rate, 6-months|Safety - Incidence of Treatment-Emergent Adverse Events according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE v4), Patients will be evaluated for treatment related adverse events (AEs) on each visit during study participation and toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE v4)., during the study, through study completion, an average of 1 year|Tolerability - treatment related adverse events (AEs) that caused study drug interruption and discontinuation, Patients will be evaluated for treatment related adverse events (AEs) that caused study drug interrupption and discontinuation., during the study, through study completion, an average of 1 year
Exploratory Biomarkers, including, but not limited to proteins and/or genes involved in regulating immune responses (eg PD-L1, IDO1, KYN and MSI status)., 6-months
A prospective, single arm, interventional study. All patients will receive IV nivolumab 3mg/kg every two weeks and ipilimumab 1mg/kg every 6 weeks. Patients will be treated until disease progression or intolerable toxicity for a maximal period of two years, with an option to re-initiate therapy upon progression in patients with prior documented response to investigational therapy (unless treatment was held for progression of disease).